Preferred Label : phenylurea compounds;

MeSH definition : Compounds that include the amino-N-phenylamide structure.;

MeSH synonym : compounds, phenylurea; phenylcarbamides; phenylurea derivatives; derivatives, phenylurea;

MeSH annotation : DF: PHENYLUREA CPDS;

Is substance : O;

Details


Main resources

You can consult :

Compounds that include the amino-N-phenylamide structure.

https://www.ema.europa.eu/en/medicines/human/EPAR/vanflyta-0
2023
false
false
false
Netherlands
French
English
treatment outcome
drug evaluation
quizartinib
quizartinib
quizartinib
FLT3 Internal Tandem Duplication
leukemia, myeloid, acute
adult
administration, oral
orphan drug production
fms-like tyrosine kinase 3
protein kinase inhibitors
protein kinase inhibitors
Tyrosine Kinase Inhibitors
package leaflet
syndication feed
summary of product characteristics
phenylurea compounds
benzothiazoles
phenylurea compounds
benzothiazoles

---
https://presse.inserm.fr/un-nouveau-traitement-entre-en-essai-clinique-chez-un-premier-enfant-achondroplase-en-france/42645
2021
false
false
false
France
French
scientific and technical information
achondroplasia
clinical trials as topic
child
france
Infigratinib
phenylurea compounds
pyrimidines
receptor, fibroblast growth factor, type 1
infigratinib

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/daurismo-5332.html
2020
false
false
false
Canada
French
drug evaluation
Glasdegib
Glasdegib Maleate
glasdegib
glasdegib
benzimidazoles
phenylurea compounds

---
https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Glasdegib
Glasdegib
benzimidazoles
benzimidazoles
phenylurea compounds
phenylurea compounds
glasdegib
antineoplastic agents
antineoplastic agents
adult
aged
antineoplastic combined chemotherapy protocols
cytarabine
leukemia, myeloid, acute
orphan drug production
administration, oral
SMO protein, human
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Glasdegib Maleate
Glasdegib Maleate
glasdegib
glasdegib
Smoothened Receptor
receptors, g-protein-coupled

---
https://www.has-sante.fr/jcms/p_3113418/fr/lenvima
2019
false
false
false
France
lenvatinib
treatment outcome
antineoplastic agents
protein kinase inhibitors
lenvatinib
adult
carcinoma, hepatocellular
administration, oral
evaluation of the transparency committee
Lenvima
phenylurea compounds
quinolines

---
https://www.has-sante.fr/portail/jcms/c_2884088/fr/fotivda-tivozanib-inhibiteur-de-proteine-kinase
2019
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
tivozanib
tivozanib
receptors, vascular endothelial growth factor
antineoplastic agents
antineoplastic agents
carcinoma, renal cell
neoplasm metastasis
adult
treatment outcome
insurance, health, reimbursement
tivozanib
Tyrosine Kinase Inhibitors
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
http://conseil-scientifique.public.lu/fr/publications/oncologie/regorafenib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
guidelines for drug use
adult
regorafenib
regorafenib
administration, oral
colorectal neoplasms
neoplasm metastasis
Metastatic colorectal cancer
gastrointestinal stromal tumors
disease progression
carcinoma, hepatocellular
protein kinase inhibitors
antineoplastic agents
survival analysis
phenylurea compounds
pyridines

---
https://www.has-sante.fr/portail/jcms/c_2884088/fr/fotivda
2018
false
false
false
France
tivozanib
tivozanib
tivozanib
administration, oral
treatment outcome
adult
carcinoma, renal cell
receptors, vascular endothelial growth factor
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
https://www.has-sante.fr/portail/jcms/c_2834705/fr/kisplyx-lenvatinib-inhibiteur-de-tyrosine-kinase
https://www.has-sante.fr/portail/jcms/c_2834705/fr/kisplyx
2018
false
false
false
France
French
lenvatinib
treatment outcome
antineoplastic combined chemotherapy protocols
carcinoma, renal cell
adult
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
lenvatinib
administration, oral
protein-tyrosine kinases
receptor Protein-Tyrosine kinases
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
disease-free survival
Everolimus
Tyrosine Kinase Inhibitors
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
Extension d'indication
https://www.has-sante.fr/portail/jcms/c_2825855/fr/stivarga-chc
2018
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
antineoplastic agents
antineoplastic agents
evaluation of the transparency committee
carcinoma, hepatocellular
phenylurea compounds
pyridines
phenylurea compounds
pyridines

---
https://www.ema.europa.eu/medicines/human/EPAR/Kisplyx
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
lenvatinib
drug approval
europe
treatment outcome
drug interactions
antineoplastic combined chemotherapy protocols
carcinoma, renal cell
adult
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
lenvatinib
administration, oral
protein-tyrosine kinases
product surveillance, postmarketing
pregnancy
breast feeding
receptor Protein-Tyrosine kinases
drug evaluation, preclinical
Product containing precisely lenvatinib (as lenvatinib mesilate) 4 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely lenvatinib (as lenvatinib mesilate) 10 milligram/1 each conventional release oral capsule (clinical drug)
Tyrosine Kinase Inhibitors
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00209
2016
false
false
false
Canada
French
English
summary of product characteristics
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
Cancer Progression
drug approval
drug evaluation, preclinical
protein-tyrosine kinases
lenvatinib
canada
Lenvatinib Mesylate
Lenvatinib Mesylate
neoplasm recurrence, local
neoplasm metastasis
Tyrosine Kinase Inhibitors
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
http://www.conseil-scientifique.public.lu/fr/publications/oncologie/sorafenib.html
http://www.conseil-scientifique.public.lu/content/dam/conseil_scientifique/publications/oncologie/sorafenib-2016.pdf
2016
false
false
true
Luxembourg
French
drug prescriptions
luxembourg
treatment outcome
survival analysis
sorafenib
thyroid carcinoma
carcinoma, hepatocellular
carcinoma, renal cell
raf kinases
antineoplastic agents
protein kinase inhibitors
receptors, vascular endothelial growth factor
receptor Protein-Tyrosine kinases
guidelines for drug use
neoplasm metastasis
Locally Advanced Malignant Neoplasm
Thyroid Gland Carcinoma
Differentiated Thyroid Gland Carcinoma
Tyrosine Kinase Inhibitors
phenylurea compounds
niacinamide
thyroid neoplasms
niacinamide
Sorafenib

---
http://www.has-sante.fr/portail/jcms/c_2044336/fr/nexavar
http://www.has-sante.fr/portail/jcms/c_2044336/fr/nexavar-sorafenib-inhibiteur-de-proteine-kinase
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
administration, oral
sorafenib tosylate
sorafenib tosylate
sorafenib
protein kinase inhibitors
protein kinase inhibitors
survival analysis
neoplasm metastasis
thyroid carcinoma
quality of life
thyroid neoplasms
phenylurea compounds
niacinamide
niacinamide
phenylurea compounds
niacinamide
Sorafenib
Sorafenib

---
Progrès thérapeutique mineur dans la prise en charge du cancer différencié de la thyroïde au stade localement avancé ou métastatique, réfractaire à l’iode radioactif
http://www.has-sante.fr/portail/jcms/c_2581320/fr/lenvima
http://www.has-sante.fr/portail/jcms/c_2581320/fr/lenvima-lenvatinib-inhibiteur-de-proteine-kinase
2015
false
false
false
France
French
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
survival analysis
neoplasm metastasis
Locally Advanced Malignant Neoplasm
evaluation of the transparency committee
Cancer Progression
lenvatinib
guidelines for drug use
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
Summary Safety Review - NEXAVAR (sorafenib) - Thyroid Gland Dysfunction
http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/nexavar-fra.php
2015
false
false
false
Canada
French
English
pharmacovigilance note
sorafenib
thyroid diseases
antineoplastic agents
risk
thyroid crisis
protein kinase inhibitors
drug monitoring
continuity of patient care
niacinamide
niacinamide
phenylurea compounds
Sorafenib

---
https://www.ema.europa.eu/medicines/human/EPAR/LENVIMA
2015
false
false
false
United Kingdom
French
English
package leaflet
summary of product characteristics
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
drug evaluation
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
Cancer Progression
syndication feed
orphan drug production
drug approval
europe
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
continuity of patient care
product surveillance, postmarketing
protein-tyrosine kinases
lenvatinib
Tyrosine Kinase Inhibitors
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
http://www.has-sante.fr/portail/jcms/c_2566483/fr/stivarga
http://www.has-sante.fr/portail/jcms/c_2566483/fr/stivarga-regorafenib-inhibiteur-de-proteine-kinase
2015
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
neoplasm metastasis
antineoplastic agents
antineoplastic agents
Progression-Free survival
evaluation of the transparency committee
Unresectable Malignant Neoplasm
gastrointestinal stromal tumors
guidelines for drug use
protein kinase inhibitors
protein kinase inhibitors
disease-free survival
phenylurea compounds
pyridines
phenylurea compounds
pyridines

---
http://www.revmed.ch/RMS/2015/RMS-N-475/Carcinome-hepatocellulaire-avance-importance-des-essais-therapeutiques
2015
false
false
false
Switzerland
French
journal article
carcinoma, hepatocellular
antineoplastic agents
phenylurea compounds
niacinamide
niacinamide
Sorafenib

---
http://www.has-sante.fr/portail/jcms/c_1743045/fr/stivarga
2014
false
France
French
regorafenib
regorafenib
regorafenib
administration, oral
treatment outcome
insurance, health, reimbursement
adult
neoplasm metastasis
colorectal neoplasms
antineoplastic agents
antineoplastic agents
Progression-Free survival
evaluation of the transparency committee
disease-free survival
phenylurea compounds
pyridines
phenylurea compounds
pyridines

---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20283
2011
false
true
false
France
phenylurea compounds
phenylurea compounds
phenylurea compounds
phenylurea compounds
herbicides
occupational exposure
toxicological data sheet
isoproturon

---
Nous contacter.
04/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.